Omnitrope 30IU cartridge
Manufacturer: Sandoz, Austria
In 1 cartridge (1.5 ml) contains:
Active substance: Somatropin (Human Growth Hormone) 10 mg (30IU);
Excipients: disodium hydrogen phosphate heptahydrate, sodium dihydrogen phosphate dihydrate, poloxamer 188, phenol, glycine, phosphoric acid, sodium hydroxide, water for injection.
Expiration date: 03.2019
1 cartridge Omnitrope 10mg / 30IU, 10 needles.
Omnitrope – Pricing Per 10 mg cartridge
|1 – 30 IU cartridges (10 MG) (1 Kit)||$95.00||$95.00|
|5 – 30 IU cartridges (10 MG) (3 Kits)||$90.00||$450.00|
|10 – 30 IU cartridges (10 MG) (6 Kits)||$88.00||$880.00|
Omnitrope can rightly be called an example of the quality of products of the Austrian company Sandoz. The product is recognized by the world, having passed many tests and analyzes, as there is relevant documentation.
This recombinant GH analogous to human growth hormone, represented by a chain of consecutively joined amino acids, Omnitrope has an anabolic effect on the human body. For the introduction of the drug, you need to use a special pen-injector (pen 10). The device can be bought in our store.
Somatropin has a pronounced effect on the metabolism of fats, proteins and carbohydrates. In children with a deficiency of growth hormone, somatropin stimulates the growth of the bones of the skeleton in length, affecting the plates of the epiphysis of tubular bones. In both adults and children, somatropin contributes to the normalization of body structure by increasing muscle mass and reducing body fat. Visceral adipose tissue is especially sensitive to the action of somatropin. In addition to enhancing lipolysis, somatropin reduces the flow of triglycerides into body fat. Under the action of somatropin, the concentration of insulin-like growth factor I (IGF-I) and its binding protein (IGF-SB3, insulin-like growth factor binding protein) increases.
You can buy Omnitrop in our store. We guarantee excellent quality and fair price. By purchasing Omnitrop from us, you can be sure that the product was stored in accordance with the requirements.
Somatropin has a pronounced effect on the metabolism of fats, proteins and carbohydrates. Somatropin helps normalize the structure of the body by increasing muscle mass and reducing body fat. Visceral adipose tissue is especially sensitive to the action of somatropin. In addition to enhancing lipolysis, somatropin reduces the flow of triglycerides into body fat. Under the action of somatropin, the concentration of insulin-like growth factor I (IGF-I) and its binding protein (insulin-like growth factor binding protein) increases.
Somatropin activates low-density lipoprotein receptors in the liver and changes the profile of lipids and lipoproteins in the blood. There is also a decrease in cholesterol concentration.
Somatropin increases the release of insulin, but the fasting glucose concentration usually does not change.
Water and mineral balance
Deficiency of growth hormone is associated with a decrease in the volume of plasma and extracellular fluid. The administration of somatropin leads to a rapid normalization of these parameters. Somatropin promotes the retention of sodium, potassium and phosphorus.
Somatropin stimulates bone metabolism. Long-term treatment of children with growth hormone deficiency and osteoporosis with somatropin leads to normalization of mineral composition and bone density.
Long-term substitution therapy with somatropin leads to an increase in muscle strength and physical endurance.
After injection, the bioavailability of somatropin is approximately 80% in both healthy individuals and in patients with growth hormone deficiency. The Omnitrop preparation at a dose of 5 mg to healthy volunteers, Cmax of somatropin in plasma and Tmax was, respectively, 72 ± 28 μg / l and 4 ± 2 hours, respectively.
The mean half-life of somatropin after intravenous administration in adults with growth hormone deficiency is about 0.4 hours. However, after subcutaneous administration of Omnitrope, an injection for 10 mg / 1.5 ml, the elimination half-life reaches 3 hours. The observed difference is probably due to a slow absorption from the injection site after subcutaneous administration.
Absolute bioavailability of somatropin after the application is not different for men and women.
Results of the study of drug interaction in adult patients with growth hormone deficiency suggest that the appointment of somatropin increases the clearance of drugs metabolized by microsomal isoenzymes of cytochrome P450, glucocorticosteroids, anticonvulsants and cyclosporine, which can lead to a decrease in their plasma concentration. The clinical significance of this effect has not yet been determined.
The effectiveness of the drug may also be affected by concomitant therapy with other hormones, for example, gonadotropin, anabolic steroids, estrogens and thyroid hormones.
Dosing and Administration Omnitrope
Omnitrope is a sterile, ready-to-use solution for subcutaneous administration, contained in a glass cartridge.
This form is for reusable use. It should only be used with the SurePal syringe pen, an injection device specially designed for use with Omnitropt. The drug should be administered with sterile disposable needles. Patients and carers should receive appropriate training and instruction in the proper use of Omnithrope and syringe-pens with a doctor or other qualified medical personnel.
The following is a general description of the administration process. Observe the manufacturer’s instructions in each syringe-pen package for loading the cartridge, attaching the needle, and for administering the drug.
Hands should be washed.
If the solution is cloudy or contains particles, it should not be used. The solution should be clear and colorless.
Disinfect the rubber membrane of the cartridge with a cleaning swab.
Install the cartridge in the SuperPal syringe pen, following the instructions for use contained in the syringe-pen package and the hypodermic needle. Set the prescribed dose.
Choose the place of introduction. The best places for injections are tissues with a layer of fat between the skin and the muscles, such as the hips or abdomen (except the navel or waist). Wipe the injection site with an alcohol swab, let the skin dry.
Enter the appropriate dose subcutaneously with a sterile SurePal syringe needle.
After injection, press the injection site with a small dressing or sterile gauze for a few seconds. Do not massage the injection site.
Separate the needle from the syringe handle using the outer needle cap, and dispose of it according to local requirements. Leave the cartridge in the syringe-pen, put the cap on the syringe-pen, and store it in the refrigerator.
Any unused product or waste must be disposed of in accordance with local requirements.
If you use more Omnitrope than you need
If you have injected a dose much more than you need, contact your doctor or pharmacist as soon as possible. Your blood sugar level may drop too low, and then rise too high.
This can lead to the development of drowsiness, increased sweating, fainting.
If you forgot to enter Omnitrope
Do not use a double dose to make up for the forgotten dose. It is best to regularly use growth hormone. If you forget to use the dose, enter the next dose at the usual time the next day. Report any missed injections to your doctor.
The doses of Omnitrope are selected individually, taking into account the severity of growth hormone deficiency, mass or body surface area, and effectiveness in the therapy process.
It is necessary to change the injection site to prevent the development of lipoatrophy.
The drug Omnitrope is administered slowly subcutaneously, the injection is performed once a day, mainly at night.
– malignant neoplasms;
– Urgent conditions (including conditions after operations on the heart, abdominal cavity, acute respiratory failure);
– growth stimulation in patients with closed epiphyseal growth zones;
– the period of breastfeeding (during the period of treatment it is necessary to refuse breastfeeding);
– Newborn period (including premature infants) due to the presence of benzyl alcohol in the composition;
– Hypersensitivity to any component of the drug.
With caution: diabetes, craniocerebral hypertension, concomitant therapy with GCS, hypothyroidism (including when carrying out substitution therapy with thyroid hormones).
For patients with a deficiency of growth hormone deficiency of extracellular volume is characteristic. At the beginning of treatment with somatropin, this deficit is quickly corrected. In adult patients, adverse reactions associated with fluid retention, such as peripheral edema, musculoskeletal stiffness, arthralgia, myalgia, and paresthesia, are common. In general, these adverse reactions from mild to moderate occur during the first months of treatment and disappear spontaneously or with a reduced dose.
The frequency of these adverse reactions is related to the dosage administered, the age of the patient, and possibly inversely proportional to the age of the patients. In children, such side effects are rare.
The introduction of Omnitrope led to the formation of antibodies in approximately 1% of patients. The binding capacity of these antibodies was low, and clinical changes were not associated with their formation.
Omnitrop can cause a state of insulin resistance, and in some patients – hyperglycemia, so you should first identify the presence of glucose intolerance. In rare cases, type 2 diabetes may develop with the use of somatropin, however, in the vast majority of these cases, the patients had risk factors such as obesity, family history or previous glucose tolerance impairment. In patients with existing diabetes mellitus, when administering somatropin, a dose adjustment of hypoglycemic drugs may be necessary.
Conditions and shelf life
18 months (for a dosage of 10 mg / 1.5 ml)
After first use, the cartridge should remain in the syringe pen and stored at a temperature of 2 оС to 8 оС (in the refrigerator) no more than 28 days.
Do not use after the expiry date printed on the package.
Omnitrop Pen 10 Video Instructions
Omnitrope Pen 10
Important Safety Information
1. Pen-injector Omnithrop Pen 10 is a precision medical device. Even if you have experience with handling such injectors, it is extremely important to carefully read this manual and follow all instructions for using the injector pen. As with any injector handles, non-observance of instructions can lead to incorrect dosage of the drug.
2. Pen-injector Omnitrop Pen 10 is designed for use with 1.5 ml cartridges containing 10 mg of somatropin. The pen can be adjusted to give any dose up to 5.4 mg, with a step of 0.1 mg. The adjustment wheel is equipped with easily readable digits and produces clicks that facilitate the installation of the desired dose.
3. People with very poor eyesight are not recommended to use the Omnitrop Pen 10 pen, if they do not have assistants with good eyesight, who can handle the pen-injector.
4. Pen-injector Omnitrop Pen 10 is supplied in a cardboard outer box containing one Omnitrop pen Pen 10 in a special case and instruction.
5. Replace the Omnitrop Pen 10 injector after 24 months of use.
Your email address will not be published. Required fields are marked *
Manufacturer: Novo Nordisk, DenmarkIn 1 box contains: NovoFine 8mm/30g needles x 100;
Expiration date: 02.2021
NovoFine 8mm/30g needles - Pricing Per 1 box 100 needles
|1 box – NovoFine 8mm/30g needles||$18.00||$18.00|
|3 box – NovoFine 8mm/30g needles||$17.00||$51.00|
|6 box – NovoFine 8mm/30g needles||$16.50||$99.00|
Expiration date: 09.2020Kit contains: 100 tablets levothyroxine sodium 100 mcg each / 4 blisters for 25 tablets
T4 L-Thyroxin - Pricing Per L-Thyroxin 100 Kit
|1 – 100 tablets kit||$16.00||$16.00|
|6 – 100 tablets kit||$15.00||$90.00|
|10 – 100 tablets kit||$14.50||$145.00|
Expiration date: -Kit contains: 1 Omnitrope Pen 10 for 10mg/1.5ml cartridge, storage case.
Omnitrope Pen 10 for 10mg/1.5ml cartridge - pricing
|1 – Omnitrope Pen 10||$25.00||$25.00|